Biofrontera (BFRI) Notes Payables (2020 - 2024)

Biofrontera (BFRI) posted quarterly Notes Payables of $296000.0 for Q2 2024, down 87.43% quarter-over-quarter from $2.4 million in Q1 2024.

Biofrontera (BFRI) Notes Payables (2020 - 2024) Analysis & Trends

Biofrontera's Notes Payables history runs 5 years deep, the most recent figure standing at $296000.0 for Q2 2024.

In Q2 2024, Notes Payables changed N/A year-over-year to $296000.0; the TTM figure through Jun 2024 stood at $296000.0 (changed N/A YoY), while the FY2023 annual figure was $3.9 million, up 197.56% from the prior year.
Notes Payables for Q2 2024 stood at $296000.0, down from $2.4 million in the prior quarter.
The five-year high for Notes Payables was $4.2 million in Q3 2022, with the low at $269000.0 in Q1 2022.
The 5-year median for Notes Payables is $1.4 million (2020), against an average of $1.7 million.
The sharpest annual moves came in 2021 and 2022: Notes Payables sank 81.66% in 2021, then surged 365.25% in 2022.
Biofrontera's Notes Payables stood at $1.5 million in 2020, then tumbled by 81.66% to $282000.0 in 2021, then soared by 365.25% to $1.3 million in 2022, then surged by 197.56% to $3.9 million in 2023, then slumped by 92.42% to $296000.0 in 2024.
Business Quant data shows BFRI's Notes Payables at $296000.0 in Q2 2024, $2.4 million in Q1 2024, and $3.9 million in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	44.40 Bn	43.44 Bn	-
2	Teva Pharmaceutical Industries	43.58 Bn	39.92 Bn	2.15 Bn
3	Zoetis	32.37 Bn	30.70 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.09 Bn	19.43 Bn	683.80 Mn
6	Viatris	19.00 Bn	18.12 Bn	1.46 Bn
7	Neurocrine Biosciences	15.47 Bn	15.08 Bn	935.80 Mn
8	Elanco Animal Health	12.04 Bn	11.51 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.97 Bn	-
10	Biofrontera	19.13 Mn	14.42 Mn	9.59 Mn

Download Data